ClinicalTrials.gg
CompletedNCT06567392Updated Oct 15, 2024

A Study to Evaluate the Mass Balance of [14C] HRS-5965 in Healthy Adult Male Volunteers

A Phase 1 interventional study of [14C] HRS-5965 in Complement Mediated Primary or Secondary Glomerular Diseases, sponsored by Chengdu Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Chengdu Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Evaluate the Mass Balance of [14C] HRS-5965 in Healthy Adult Volunteers.

02

Conditions studied

  • Complement Mediated Primary or Secondary Glomerular Diseases
03

In context

Lead sponsor

Chengdu Suncadia Medicine Co., Ltd. is the lead sponsor of 24 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the form prior to the trial and have a full understanding of the trial's procedures, content, and potential adverse reactions;
  2. Healthy adult males between 18 and 45 years;
  3. Body weight ≥50 kg, and the (BMI) of 19 to 26 kg/m2;
  4. From the signing of the informed consent form until 12 months after the last administration, the subject (including partner) has no family planning and is willing to use the high-efficiency measures specified in the plan.

Exclusion criteria

Exclusion Criteria:

  1. Comprehensive physical examination, vital signs, laboratory tests (blood routine, blood biochemistry, coagulation function, urine analysis, fecal analysis, thyroid function), full chest anteroposterior and lateral film, abdominal ultrasound, and anoscope results that the researcher deems .
  2. Patients with >450 msec at the time of screening or baseline, or 12 lead examination are abnormal and determined by the researcher to have clinical significance.
  3. Patients with clinically significant abnormalities in ophthalmic examinations (color vision, slit lamp, intraocular pressure, and fundus photography).
  4. Patients whose blood creatinine levels exceed the values.
  5. (ALT) or aspartate aminotransferase (AST) exceeding the upper limit of normal values (ULN), or total exceeding 1.5 times ULN.
  6. surface antigen (HBsAg) positive, or anti virus (HCV) antibody positive, or (HIV) antibody positive, or Treponema pallidum antibody positive.
  7. Abuse of drugs or use of soft drugs (such as marijuana) in the three months prior to screening, or use of hard drugs (such as amphetamines, phencyclidine, etc.) in the year prior to screening; Or screening period urine drug test positive individuals.
  8. Patients used any drugs (including prescription drugs, over-the-counter drugs, Chinese herbal medicines, traditional Chinese patent medicines and simple preparations and dietary supplements) within 4 weeks before screening; Or select those who are within 5 half-lives of the drug at the time of screening (whichever is longer).
  9. Patients who are allergic to two or more allergens, or who have been determined by the researcher to be potentially allergic to the drug or its components 11. Any clinical history of serious diseases or conditions that the researcher believes may affect the trial results, including but not limited to a history of circulatory, endocrine, nervous, digestive, urinary, or blood, immune, mental, and metabolic diseases.
  10. According to the judgment of researchers, there may be diseases or medical conditions that may affect drug absorption, distribution, metabolism, and excretion, or may reduce compliance.
  11. Patients with combined diseases of the respiratory, circulatory, digestive, urinary, psychiatric, hematological, endocrine, metabolic, and immune systems.
  12. Patients with a history of meningococcal infection or first-degree relatives with a history of meningococcal infection.
  13. Screening for individuals with clear evidence of infection (positive pathogen test or previous systemic antibiotic treatment) or those with a body temperature above 38 ℃ within the first 2 weeks.
  14. Screening for individuals with severe trauma or surgery within the first 8 weeks, or those planning to undergo surgery during the trial period.
  15. Subjects with a history of recurrent oral ulcers.
  16. Perianal diseases with hemorrhoids or periodic/ongoing rectal bleeding; The subject is unable to swallow or has difficulty swallowing, or has a history of gastrointestinal dysfunction such as irritable bowel syndrome, inflammatory bowel disease, or has undergone surgery such as gastrectomy, which the researcher determines may affect drug absorption.
  17. Habitual constipation or diarrhea, irregular or difficult bowel movements, or other situations that have been evaluated by the researcher and affect the collection of fecal samples.
  18. Have a history of severe vomiting.
  19. Screening for individuals who smoke an average of 5 or more cigarettes per day within the first 4 weeks, or who are unable to quit nicotine containing products (including nicotine patches) during the trial period.
  20. The average daily intake of alcohol in the four weeks before screening exceeds 15 g (15 g of alcohol is equivalent to 450 mL of beer, 150 mL of wine or 50 mL of low alcohol Baijiu), or the alcohol breath test is positive during screening, or the patient uses or drinks any food or drink containing alcohol within 48 hours before administration, or cannot quit during the test.
  21. Habitually drinking grapefruit or grapefruit juice or orange juice, or products containing caffeine or xanthine (such as coffee, tea, cola drinks, and chocolate), or using these products within 48 hours before administration, or unable to quit during the trial period.
  22. Clinical trials involving any other drug or medical device within the first 3 months of screening or planned to be conducted during the study period, or those who are still within 5 half-lives of the drug before screening (whichever is longer).
  23. Vaccines administered within 2 weeks prior to the first administration or planned during the study period and within 1 month after the last administration.
  24. Individuals with a history of blood donation or severe blood loss (blood loss ≥ 400 mL) within the 8 weeks prior to screening, or those who have received a blood transfusion within the 12 weeks prior to screening.
  25. Engaged in workers who require long-term exposure to radioactive conditions; Or select individuals who have had significant radiation exposure (chest/abdominal CT ≥ 2 times, or other types of X-ray examinations ≥ 3 times) or participated in radiopharmaceutical labeling trials within the previous year.
  26. Difficulty in venous blood collection or inability to withstand blood collection due to physical condition; Or subjects who are expected to be unable to complete the entire trial follow-up.
  27. The researcher determined that the subjects had other factors that were not suitable for participation in this study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C] HRS-5965

    Drug: [14C] HRS-5965

Interventions

  • Patients will receive single dose of orally \[14C\] HRS-5965 on Day 1.

06

What researchers measure

Primary outcomes

  1. Total radioactive recovery rate in urine and feces at each time interval

    Time frame: 0-240 hours

  2. Cumulative total radioactive recovery rate in urine and feces

    Time frame: 0-240 hours

  3. 3. Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC)

    Time frame: 0-192 hours

  4. Percentage of parent drug and its metabolites in urine and feces as a percentage of administered dose (%Dose)

    Time frame: 0-240 hours

  5. Radioactivity Tmax

    Time frame: 0-192 hours

  6. Radioactivity Cmax

    Time frame: 0-192 hours

  7. Radioactivity AUC

    Time frame: 0-192 hours

  8. Radioactivity t1/2

    Time frame: 0-192 hours

  9. Radioactivity CL/F

    Time frame: 0-192 hours

  10. Radioactivity Vz/F

    Time frame: 0-192 hours

  11. Total radioactivity ratio for blood/plasma

    Time frame: 0-96 hours

Secondary outcomes

  1. Plasma HRS-5965: Tmax

    Time frame: 0-192 hours

  2. Plasma HRS-5965: Cmax

    Time frame: 0-192 hours

  3. Plasma HRS-5965: AUC

    Time frame: 0-192 hours

  4. Plasma HRS-5965: t1/2

    Time frame: 0-192 hours

  5. Plasma HRS-5965: CL/F

    Time frame: 0-192 hours

  6. Plasma HRS-5965: Vz/F

    Time frame: 0-192 hours

  7. Plasma HRS-5965: λz

    Time frame: 0-192 hours

  8. AEs and SAEs

    Time frame: 0-11 days

07

Study locations

1 site
  • The First Affiliated Hospital Of Shandong First Medical University(Shandong Provincial Qianfoshan Hospital)
    Jinan, Shandong 250014, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Oct 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2024
First posted
Aug 22, 2024
StartActual
Sep 3, 2024
Primary completionActual
Oct 8, 2024
CompletionActual
Oct 8, 2024
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06567392
Responsible party
Sponsor
First posted
Aug 22, 2024
Start date
Sep 3, 2024
Primary completion
Oct 8, 2024
Completion
Oct 8, 2024
Last update
Oct 15, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-5965

Start the discussion